Discontinuation report KOMBOGLYZE
| Report ID | 265936 |
| Drug Identification Number | 02389185 |
| Brand name | KOMBOGLYZE |
| Common or Proper name | saxagliptin and metformin hydrochloride tablets |
| Company Name | ASTRAZENECA CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | SAXAGLIPTIN METFORMIN HYDROCHLORIDE |
| Strength(s) | 2.5MG 1000MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 60 tablets |
| ATC code | A10BD |
| ATC description | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2026-02-26 |
| Actual discontinuation date | |
| Remaining supply date | 2026-02-26 |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: medinfo.canada@astrazeneca.com. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2025-08-26 | French | Compare |
| v1 | 2025-08-26 | English | Compare |
Showing 1 to 2 of 2